Forecast: top 10 best-selling drugs in oncology in 2023

The checkpoint inhibitor race has begun, with a brand new class of cancer drugs achieving unprecedented results in efficacy.

Source: GlobalData Pharma Intelligence Centre, Drugs Database [accessed 16 November 2017]

It is no surprise that the three best-selling oncology drugs are immuno-modulating agents. The checkpoint inhibitor race has begun, with a brand new class of cancer drugs achieving unprecedented results in efficacy. Successful companies are employing strategies similar to other mega-blockbuster drugs such as Avastin and Herceptin.

Celgene’s Revlimid, already a cancer blockbuster drug, is currently demonstrating its effectiveness in 18 cancer trials and is already marketed for eight indications. Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo are trailing in the second and third positions, respectively; these PD1 inhibitors have created new opportunities for developers to explore a range of potential label expansions with unprecedented data.

Immuno-oncology drugs have paved the way for pharma and biotech companies to be creative in their trials and explore the use of immune-modulators in combination with chemotherapy/targeted therapy agents or as backbone therapies for immuno-oncology candidates. The benefits of market access for checkpoint inhibitors are plentiful; and developers have the upper-hand in a bottom-up approach to markets and gaining first-to-market and first-in-class approvals.

Free Whitepaper

Precision Medicine: Streamlining Treatments and Drug Development

Precision medicine has the potential to radically change the way health services are delivered, combining medical expertise with the latest technology to provide bespoke treatments for individual patients. Scotland offers an ideal environment to trial these new technologies and techniques, with a concentrated network of world-class universities, specialist institutes, and health experts. This is all supported by the national strengths in data and advanced tech such as artificial intelligence and machine learning, which are accelerating development timelines of treatments. Then there is the funding support available. Partnerships with universities allow companies to apply for UK funding streams. And Scottish universities have a track record of securing UK funding. In the last five years, through the Biotechnology and Biological Sciences Research Council and Medical Research Council, 13% (£450m) of all UK funding has gone to universities in Scotland. Download to learn more.

By Scotland

By downloading this case study, you acknowledge that GlobalData may share your information with Scotland and that your personal data will be used as described in their Privacy Policy

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.